infect
defin
patholog
process
caus
invas
normal
steril
tissu
fluid
bodi
caviti
pathogen
potenti
pathogen
microorgan
sepsi
defin
presenc
organ
dysfunct
occur
result
dysregul
host
respons
infect
young
patient
obviou
meningococc
rash
high
fever
alter
mental
statu
diagnosi
sepsi
fairli
straightforward
alway
case
especi
amongst
critic
ill
popul
multipl
comorbid
ongo
diseas
process
first
clinic
sign
sepsi
fever
usual
typic
specif
similarli
leukocytosi
nonspecif
typic
sign
laboratori
paramet
arteri
hypotens
lactat
accumul
often
late
symptom
associ
organ
dysfunct
rise
mortal
rate
tradit
laboratori
method
confirm
diagnosi
infecti
diseas
involv
microbi
identif
reli
morpholog
featur
growth
characterist
biochem
substrat
microbiologist
search
rapid
effici
mean
microbi
identif
nucleic
acid
amplif
technolog
pcr
open
new
frontier
microbi
identif
advent
molecular
diagnost
provid
tool
faster
diagnosi
infect
even
pcrbase
method
time
limit
perform
within
half
hour
requir
poc
diagnosi
infect
nonpcr
method
develop
purpos
role
biomark
detect
rapidli
explor
diagnosi
infect
howev
continu
requir
critic
clinic
awar
care
patient
histori
dedic
physic
examin
appropri
cultur
diagnost
spectrum
variou
marker
howev
differ
mani
biomark
implic
play
harm
mediat
role
sepsi
primarili
indic
sever
inflamm
eg
other
respond
infect
indic
host
respons
well
endotoxin
lipoprotein
bind
protein
trigger
receptor
myeloid
cell
recent
data
cumul
analys
indic
biomark
sepsi
improv
diagnosi
sepsi
biomark
impact
therapi
fulfil
clinic
requir
characterist
ideal
biomark
infect
high
level
sepsi
posit
correl
sever
infect
prolong
persist
blood
enabl
earli
diagnosi
rapid
accur
bedsid
measur
indic
cours
prognosi
diseas
facilit
therapeut
decis
sever
studi
indic
prohormon
procalcitonin
biomarkermedi
sepsi
possess
great
potenti
meet
criteria
therapeut
immunoneutr
human
merit
evalu
proteom
technolog
use
detect
protein
biomark
infect
exampl
novel
mass
spectral
fingerprint
proteom
approach
use
malditof
ms
appli
detect
identifi
protein
biomark
group
streptococcu
ga
strain
moura
et
al
specif
biomark
found
strain
invas
ga
isol
could
differenti
ga
isol
case
necrot
fasciiti
cluster
togeth
distinct
isol
associ
noninvas
infect
endotheli
cell
play
key
role
inflammatori
respons
trigger
sepsi
proteom
technolog
use
investig
secretom
endotheli
cell
follow
lipopolysaccharid
stimul
lp
secretom
dynam
respons
lp
analyz
onlin
system
kwon
et
al
candid
protein
author
focus
moesin
membraneorgan
extens
spike
protein
involv
function
endotheli
cell
confirm
amount
cellular
lysat
media
taken
primari
human
umbil
vein
endotheli
cell
treat
lp
find
indic
moesin
potenti
biomark
sepsi
difficulti
diagnos
sepsi
organ
dysfunct
avail
accur
sepsi
biomark
facilit
diagnosi
could
use
enabl
time
appropri
treatment
start
thu
optim
patient
chanc
surviv
biomark
propos
assess
clinic
includ
variou
cytokin
cell
surfac
biomark
receptor
complement
factor
coagul
factor
acut
phase
reactant
mani
other
none
specif
sepsi
perhap
wide
studi
biomark
sepsi
crp
whose
role
host
defens
bacteria
known
almost
year
howev
crp
sensit
specif
increas
inflammatori
disord
includ
uncompl
surgeri
pct
first
propos
biomark
perhap
specif
biomark
crp
although
also
increas
inflammatori
condit
pancreat
polytrauma
major
surgeri
biomark
play
role
help
identifyor
perhap
importantli
rule
outan
infect
infect
allornon
phenomenon
gray
area
one
never
realli
certain
infect
present
absent
high
sensit
sepsi
marker
usual
help
rule
rule
infect
particularli
true
critic
ill
patient
often
inflammatori
respons
alway
infect
requir
antibiot
administr
henc
sepsi
biomark
rule
infect
could
help
decreas
use
unnecessari
antibiot
limit
use
excess
imag
procedur
search
possibl
sourc
encourag
clinician
search
altern
diagnos
one
exampl
use
biomark
use
pct
rule
infect
febril
patient
present
emerg
depart
patient
suspect
lower
respiratori
tract
infect
use
antibiot
less
discourag
base
pct
concentr
result
signific
reduct
antibiot
use
second
question
relat
role
assess
sever
diseas
primarili
triag
decis
eg
whether
admit
patient
emerg
room
gener
ward
icu
exampl
use
biomark
demonstr
hospit
patient
show
mortal
rate
time
higher
patient
present
sepsi
gener
ward
pct
concentr
ngml
lower
pct
level
giamarellosbourbouli
et
al
author
suggest
pct
concentr
could
thu
use
help
identifi
patient
may
benefit
icu
admiss
third
question
relat
role
monitor
patient
respons
therapi
role
particular
trend
concentr
time
clearli
valu
singl
measur
pct
crp
wide
studi
biomark
context
mortal
rate
substanti
lower
septic
patient
pct
concentr
decreas
h
patient
karlsson
et
al
similarli
pattern
chang
crp
concentr
correl
individu
clinic
cours
patient
communityacquir
sepsi
povoa
et
al
progress
declin
crp
pct
concentr
use
guid
earlier
discontinu
antibiot
therapi
without
major
risk
increas
crp
concentr
first
h
therapi
suggest
antibiot
therapi
may
ineffect
need
reevalu
pct
level
use
guid
antibiot
therapi
sever
clinic
trial
differ
group
infect
patient
promis
result
antibiot
use
howev
use
pct
concentr
antibioticescal
strategi
wise
strategi
may
result
wors
outcom
clearli
clinic
decis
base
concentr
singl
biomark
must
includ
evalu
clinic
statu
patient
hemodynam
laboratori
paramet
sever
biomark
sepsi
current
avail
list
tabl
mitochondri
damag
dysfunct
consid
play
import
role
pathogenesi
sepsisinduc
organ
failur
unfortun
pauciti
specif
biomark
mitochondri
damag
vital
organ
carbomyl
phosphat
synthas
cp
protein
primarili
local
liver
mitochondria
present
high
concentr
plasma
patient
sepsi
prospect
random
control
anim
studi
verifi
circul
biomark
mitochondri
damag
deplet
liver
subacut
phase
sepsi
crouser
et
al
mechanist
standpoint
mitochondri
deplet
due
cell
death
appar
relat
remov
damag
mitochondria
lysosom
follow
replet
mitochondri
popul
restor
mitochondri
popul
liver
reduc
level
appear
signal
recoveri
sepsi
may
superior
convent
biomark
liver
damag
sepsi
studi
need
determin
clinic
util
biomark
sever
sepsi
relationship
level
inflammatori
vascular
endotheli
biomark
assess
use
pearson
spearman
correl
analysi
prospect
random
trial
simvastatin
versu
placebo
patient
septic
shock
donnino
et
al
level
significantli
decreas
patient
septic
shock
compar
healthi
control
invers
associ
vascular
endotheli
biomark
inflammatori
molecul
though
associ
diminish
adjust
level
low
densiti
lipoprotein
ldl
cho
lesterol
primari
transport
molecul
vascular
cell
adhes
molecul
vcam
remain
lower
follow
adjust
analysi
identifi
low
level
septic
shock
signific
compound
essenti
mitochondri
function
may
play
import
role
pathophysiolog
mitochondri
dysfunct
sepsi
open
possi
biliti
potenti
therapeut
intervent
administ
exogen
failur
clinic
trial
septic
shock
partli
due
inequit
unknown
distribut
baselin
mortal
risk
studi
arm
intervent
trial
septic
shock
requir
effect
outcom
risk
stratif
genomewid
express
studi
identifi
plasma
protein
candid
biomarkerbas
risk
stratif
multibiomarkerbas
outcom
risk
stratif
model
adult
septic
shock
includ
five
candid
biomark
admiss
lactat
concentr
age
chronic
diseas
burden
sensit
mortal
specif
posit
predict
valu
neg
predict
valu
wong
et
al
calibr
decis
tree
follow
test
characterist
valid
cohort
sensit
specif
posit
predict
valu
neg
predict
valu
wealth
data
implic
nitric
oxid
key
player
cardiac
vascular
renal
pulmonari
derang
sepsi
septic
shock
cytokin
activ
induc
nitric
oxid
synthas
ino
express
produc
excess
amount
caus
shock
sepsi
cytokin
constitut
molecular
biomark
intercellular
messeng
inflamm
septic
shock
septic
shock
occur
exacerb
inflammatori
respons
damag
tissu
mitochondria
skelet
muscl
appear
one
main
target
organ
septic
shock
show
increas
product
earli
oxid
stress
contractil
failur
mitochondria
isol
rat
human
skelet
muscl
septic
shock
show
markedli
increas
gener
decreas
state
respir
mark
nicotinamid
adenin
dinucleotid
nad
link
substrat
succin
without
uncoupl
impair
phosphoryl
one
current
hypothes
molecular
mechan
septic
shock
enhanc
product
mitochondri
no
lead
excess
peroxynitrit
product
protein
nitrat
mitochondri
matrix
mitochondri
dysfunct
contractil
failur
research
diagnost
antibodi
wwwrdantibodiescom
conduct
clinic
studi
involv
icu
patient
use
test
base
antiino
mab
compani
receiv
million
grant
nation
institut
gener
medic
scienc
support
pivot
clinic
studi
test
design
obtain
fda
clearanc
test
base
novel
plasma
biomark
discov
compani
identifi
patient
develop
sepsi
patholog
h
prior
appear
symptom
current
use
physician
indictor
onset
sepsi
enabl
treat
patient
effect
start
antibiot
treatment
fluid
resuscit
sooner
test
yet
approv
regulatori
author
prospect
cohort
studi
evalu
solubl
form
urokinasetyp
plasminogen
activ
supar
earli
prognost
biomark
sepsi
patient
suspect
infect
et
al
supar
measur
admiss
use
commerci
solidphas
elisa
cutoff
level
ng
ml
supar
sensit
specif
fatal
diseas
cutoff
level
ng
ml
sensit
specif
sever
sepsi
respect
level
significantli
higher
nonsurvivor
compar
survivor
patient
sever
sepsi
compar
group
high
supar
independ
predictor
case
fatal
sever
inflammatori
respons
syndrom
sir
chemokin
superfamili
small
peptid
involv
leukocyt
chemotaxi
induct
cytokin
wide
rang
infecti
diseas
peptid
secret
tissu
cell
leucocyt
activ
epitheli
cell
four
differ
subfamili
identifi
base
highli
conserv
presenc
first
two
cystein
residu
either
separ
amino
acid
cc
chemokin
cxc
chemokin
chemokin
c
chemokin
chemokin
act
famili
chemokin
receptor
present
cell
type
leukocyt
dendrit
cell
endotheli
cell
chemo
kine
receptor
play
import
role
innat
immun
infecti
diseas
hivaid
malaria
measur
serum
level
cxc
cc
chemokin
initi
phase
meningococc
sepsi
children
predict
mortal
correl
strongli
diseas
sever
chemokin
may
play
key
role
pathophysiolog
meningococc
diseas
potenti
new
target
therapeut
approach
endotoxin
candid
diagnost
tool
infect
sever
year
howev
inconsist
increas
level
variat
sensit
specif
differ
patient
group
lack
correl
sever
inflamm
host
respons
support
clinic
use
reevalu
highli
sensit
biolog
assay
approv
fda
use
us
endotoxin
activ
assay
spectral
diagnost
inc
quit
sensit
base
exvivo
whole
blood
measur
system
measur
zymosanand
antiendotoxinantibodi
elicit
respiratori
burst
kinet
luminometr
assay
antibodi
direct
lipopolysaccharid
variou
gramneg
bacteria
despit
good
biomark
exclus
infect
indic
well
host
respons
indic
clinic
use
test
thu
limit
exclus
infect
patient
admit
icu
low
respons
sever
infect
may
limit
valu
guid
therapi
also
low
specif
may
restrict
clinic
use
futur
studi
indic
whether
biomark
similar
sensit
given
low
specif
procalcitonin
proct
precursor
peptid
hormon
calcitonin
ct
better
fulfil
requir
desir
biomark
compar
other
solid
scientif
basi
translat
ctmrna
proct
cleav
enzymat
smaller
peptid
final
yield
amino
acid
matur
ct
ct
precursor
peptid
includ
proct
found
serum
normal
person
microbi
infect
variou
form
inflamm
circul
level
sever
calcitonin
precursor
includ
proct
matur
ct
increas
sever
thousandfold
increas
especi
cours
correl
sever
condit
mortal
microbi
infect
induc
increas
calci
geneexpress
releas
proct
parenchym
tissu
differenti
cell
type
throughout
bodi
commerci
avail
assay
base
timeresolv
amplifi
cryptat
emiss
technolog
pct
brahmsthermofish
scientif
use
sheep
polyclon
anticalcitonin
antibodi
monoclon
antikatacalcin
antibodi
bind
calcitonin
katacalcin
sequenc
calcitonin
precursor
molecul
diagnost
accuraci
proct
shown
varieti
infect
eg
respiratori
tract
infect
mening
acut
infecti
endocard
pancreat
colorimetr
quick
bedsid
version
test
advantag
rapid
determin
circul
ctpr
level
min
assay
semiquantit
sensit
enough
detect
moder
elev
proct
level
proctbas
therapeut
strategi
safe
markedli
reduc
antibiot
usag
lower
respiratori
tract
infect
major
caus
sepsi
hormokin
mediat
immunoneutr
proct
might
offer
new
hope
effect
treatment
option
sepsi
evid
proct
provid
inform
therebi
question
current
use
gold
standard
diagnosi
clinic
relev
bacteri
infect
yet
proct
less
perfect
biomark
proct
increas
noninfecti
condit
may
remain
low
infect
random
intervent
trial
conduct
patient
suspect
communityacquir
pneumonia
univers
hospit
basel
switzerland
assess
proct
guidanc
initi
durat
antibiot
therapi
christcrain
et
al
primari
endpoint
antibiot
use
secondari
endpoint
measur
clinic
laboratori
radiograph
outcom
proct
guidanc
reduc
total
antibiot
exposur
antibiot
prescript
admiss
antibiot
treatment
durat
compar
patient
treat
accord
guidelin
measur
proct
reduc
length
antibiot
treatment
averag
day
proct
appear
reliabl
measur
individu
tailor
earli
discontinu
antibiot
therapi
compar
routin
use
clinic
paramet
also
timeand
costeffect
took
less
min
detect
level
serum
procalcitonin
laboratori
result
routin
avail
within
hour
test
cost
prognosi
patient
sever
sepsi
septic
shock
admit
intens
care
unit
icu
may
associ
proct
result
prospect
analysi
patient
sepsi
admit
icu
indic
dynam
chang
pct
reflect
day
day
admiss
icu
may
serv
predictor
surviv
critic
ill
patient
sever
sepsi
huang
et
al
solubl
urokinas
plasminogen
activ
receptor
supar
protein
blood
measur
elisa
assay
virog
ceivd
mark
doubl
mab
sandwich
assay
sampl
peroxidaseconjug
antisupar
first
mix
togeth
incub
antisupar
precoat
microwel
recombin
supar
standard
kit
calibr
healthi
human
blood
donor
sampl
supar
concentr
given
ngml
plasma
prospect
cohort
studi
show
plasma
supar
level
sensit
specif
independ
prognost
biomark
patient
bacteremia
huttunen
et
al
individu
level
high
increas
chanc
neg
outcom
critic
condit
septicemia
unless
appropri
treatment
administ
earli
lower
level
thu
measur
individu
level
prognosi
assess
need
therapi
indic
effect
treatment
monitor
sepsi
defin
system
inflammatori
respons
syndrom
sir
identifi
focu
infect
onset
sepsi
massiv
inflammatori
reaction
involv
chemic
mediat
cytokin
chemokin
inflammatori
cell
polymorphonuclear
neutrophil
macrophag
take
place
addit
system
inflammatori
process
sepsi
septic
shock
caus
profound
decreas
peripher
vasomotor
tone
lead
great
decreas
peripher
resist
event
central
derang
hemodynam
perfus
paramet
sir
also
precipit
noninfect
event
trauma
pancreat
surgeri
consequ
overact
sir
respons
function
variou
organ
system
may
compromis
result
multipl
organ
dysfunct
syndrom
death
effort
made
identifi
biomark
prognosi
sir
sepsi
caus
estim
death
annual
us
worldwid
cost
treat
septic
patient
intens
care
unit
icu
add
per
day
cost
patient
care
chromogranin
cga
biomark
stress
releas
catecholamin
adren
medulla
previous
associ
cardiovascular
diseas
cancer
serum
cga
concentr
significantli
increas
sir
patient
compar
healthi
control
highest
increas
cga
seen
patient
infect
associ
sir
cga
concentr
posit
correl
biomark
inflamm
procalcitonin
crp
well
simplifi
acut
physiolog
score
sap
patient
cga
concentr
significantli
shorter
surviv
zhang
et
al
mycobacterium
tuberculosi
common
bacteri
infect
world
affect
approxim
billion
peopl
infect
world
neglect
health
problem
kill
million
peopl
year
infecti
diseas
combin
unless
diagnos
activ
tb
oftenfat
condit
patient
activ
tb
spread
diseas
averag
other
per
year
tuberculosi
incid
increas
develop
develop
countri
one
reason
sharp
increas
tb
infect
develop
antibiot
resist
tb
strain
includ
resist
multipl
drug
world
health
organ
estim
diseas
infect
billion
person
claim
million
live
next
year
us
alon
approxim
million
resid
infect
worldwid
one
three
person
harbor
caus
organ
tuberculosi
accord
billion
tb
test
perform
yearli
number
project
increas
tuberculosi
reemerg
import
caus
human
diseas
particularli
hivinfect
patient
experi
sever
immunosuppress
approxim
case
tb
associ
hiv
tuberculosi
infect
predominantli
involv
lung
halt
spread
tuberculosi
requir
multifacet
approach
incorpor
earli
diagnosi
appropri
antimicrobi
therapi
proper
patient
isol
screen
highrisk
popul
enhanc
laboratori
biosafeti
effort
prevent
latetwentiethcenturi
epidem
becom
major
scourg
twentyfirst
centuri
laboratori
personnel
method
play
key
role
earli
prompt
diagnosi
particularli
hivinfect
individu
reduc
morbid
mortal
tuberculosi
uniqu
natur
organ
infect
tuberculosi
ultim
develop
diseas
consider
research
plan
area
institut
singapor
govern
invest
million
investig
biomark
identifi
individu
may
risk
develop
tuberculosi
help
guid
drug
therapi
part
project
joint
laboratori
creat
biopoli
singapor
research
agenc
scienc
technolog
research
singapor
immunolog
network
sign
studi
immun
cell
blood
patient
infect
tb
whose
diseas
inact
cell
compar
patient
activ
tb
healthi
control
order
identifi
potenti
biomark
tb
infect
tb
reactiv
addit
aid
diagnosi
diseas
research
could
help
clinician
assess
monitor
patient
respons
tb
treatment
manag
develop
drugresist
tuberculosi
tuberculosi
gener
diagnos
combin
gener
specif
symptom
along
find
variou
laboratori
test
two
wide
use
test
tuberculin
skin
test
acidfast
microscop
smear
although
provid
rapid
result
neither
especi
reliabl
skin
test
distinguish
latent
infect
activ
tuberculosi
addit
distinguish
tuberculosi
atyp
mycobacterium
prove
difficult
microscop
reliabl
detect
larg
number
organ
must
present
sputum
smear
posit
onehalf
threequart
case
cultur
distinguish
mycobacteria
atyp
form
determin
antibiot
sensit
take
long
week
distinct
import
atyp
form
mycobacteria
respond
convent
antibiot
time
lag
diagnosi
howev
delay
isol
contagi
diseas
initi
treatment
emerg
multidrugresist
mdr
tuberculosi
aggrav
attempt
erad
infect
mdr
organ
resist
convent
antimicrobi
therapi
also
associ
high
mortal
rapid
occurr
death
molecular
technolog
avail
provid
detect
identif
antimicrobi
sensit
test
mycobacteria
ideal
molecular
probe
would
provid
function
directli
clinic
sampl
sensit
cultur
matter
hour
rather
week
rapid
result
essenti
provid
optim
care
patient
infect
tuberculosi
mycobacterium
speci
limit
spread
tuberculosi
fda
approv
amplifi
mycobacterium
tuberculosi
direct
amtd
test
genprob
san
diego
california
variou
studi
afb
acidfast
bacilli
smear
cultur
sensit
amtd
specif
test
combin
genprob
transcriptionmedi
amplif
hpa
technolog
yield
result
h
use
patient
cultiv
tuberculosi
continu
shed
microorgan
addit
amtd
aid
monitor
patient
treat
antitubercular
drug
largescal
studi
initi
aim
identifi
biomark
tuberculosi
infect
diseas
key
find
recent
one
factor
seem
abl
explain
complex
cours
tuberculosi
infect
multifactori
analys
identifi
varieti
gene
protein
mostli
involv
bacteri
persist
host
respons
offer
promis
biomark
differ
diseas
stage
candid
biomark
differenti
peopl
activ
tuberculosi
healthi
individu
normal
therapi
reproduc
predict
clinic
outcom
divers
patient
popul
although
larg
number
promis
candid
biomark
examin
date
patient
studi
reach
clinic
meaning
outcom
studi
conduct
intern
research
standard
challeng
valid
suggest
biomark
describ
reduc
clinic
practic
done
offer
possibl
greatli
improv
clinic
manag
tuberculosi
allow
segreg
patient
contact
appropri
treatment
regimen
diagnosi
tubercul
mening
tbm
difficult
rapid
confirmatori
diagnosi
essenti
initi
requir
therapi
presenc
kd
heat
shock
protein
hsp
antigen
csf
confirm
suspect
case
tbm
would
indic
select
protein
specif
tuberculosi
could
consid
diagnost
biomark
tbm
pulmonari
tuberculosi
may
alter
volatil
organ
compound
voc
breath
mycobacteria
oxid
stress
result
mycobacteri
infect
gener
distinct
voc
studi
condct
determin
breath
voc
contain
biomark
activ
pulmonari
tuberculosi
phillip
et
al
head
space
voc
cultur
mycobacterium
tuberculosi
captur
sorbent
trap
assay
ga
chromatographymass
spectroscopi
gcm
breath
voc
assay
gcm
patient
hospit
suspicion
pulmonari
tuberculosi
healthi
control
sputum
cultur
posit
mycobacteria
neg
patient
pattern
recognit
analysi
fuzzi
logic
analysi
breath
voc
independ
distinguish
healthi
control
hospit
patient
sensit
specif
studi
conclud
volatil
biomark
breath
sensit
specif
pulmonari
tuberculosi
breath
test
distinguish
sick
versu
well
ie
normal
control
patient
hospit
suspicion
pulmonari
tuberculosi
infect
versu
noninfect
patient
ie
whose
sputum
cultur
posit
neg
mycobacteria
howev
sinc
find
deriv
compar
small
pilot
studi
confirm
requir
addit
studi
larger
number
patient
wherea
viral
infect
test
either
immunoassay
dna
latter
provid
benefit
earlier
specif
accur
test
immunoassay
detect
presenc
antibodi
viru
measur
immun
system
actual
produc
antibodi
blood
diseas
hiv
hepat
antibodi
gener
lag
behind
infect
long
month
dna
test
hand
look
antigen
viru
necessari
wait
bodi
produc
antibodi
thu
provid
earlier
detect
biochem
test
infect
prone
human
error
requir
extens
qualiti
control
new
lot
biochemicalbas
identif
take
sever
day
compar
sever
hour
dnabas
test
approxim
acut
viral
hepat
case
due
familiar
hepat
ae
virus
diagnosi
hepat
e
serolog
marker
usual
adequ
contrast
molecular
diagnosi
import
hepat
b
c
caus
hepat
infect
nearli
case
continu
baffl
physician
common
caus
viral
hepat
worldwid
small
singlestrand
rna
viru
belong
enteroviru
genu
picornaviru
famili
hav
infect
usual
produc
brief
ill
lead
chronic
carrier
state
chronic
hepat
pcrbase
assay
use
detect
hav
antibodi
well
differenti
genotyp
ii
addit
modifi
pcr
test
detect
intact
viru
particl
ignor
fragment
genet
materi
viru
destroy
steril
process
method
blood
product
incub
havspecif
monoclon
antibodi
viral
rna
transcrib
amplifi
identifi
dna
antibodi
captur
intact
viru
pcr
test
identifi
viral
nucleic
acid
make
falseposit
result
less
like
approxim
million
chronic
carrier
hbv
worldwid
repres
global
health
care
challeng
exposur
contamin
blood
major
sourc
infect
mode
transmiss
possibl
eg
inocul
ocular
surfac
corneal
transplant
chronic
hbv
infect
respons
much
world
liver
cirrhosi
implic
high
percentag
case
liver
cancer
situat
screen
viru
warrant
includ
follow
clinic
suspicion
hepat
b
blood
donor
blood
product
monitor
respons
vaccin
hbv
difficult
cultur
presenc
typic
demonstr
electron
microscopi
although
exist
hbv
surfac
antigen
hbsag
serum
plasma
indic
hbv
infect
detect
hbsag
provid
inform
replic
activ
viru
hepanostika
hbsag
ultra
assay
biomerieux
ceapprov
test
launch
europemiddl
east
offer
stateoftheart
sensit
excel
specif
detect
hbv
surfac
antigen
human
plasma
serum
level
hbv
dna
serum
plasma
probabl
reflect
replic
activ
hbv
variou
techniqu
detect
hbv
dna
develop
includ
hybrid
assay
gener
quantit
result
lack
sensit
pcr
offer
superior
sensit
predict
qualit
result
though
find
import
treatment
guid
method
quantit
assess
hbv
dna
includ
bayer
hbv
dna
assay
abbott
hbv
dna
assay
monitor
level
hbv
may
help
identifi
individu
like
respond
antivir
therapi
evalu
efficaci
therapi
track
infect
viral
burden
therapi
monitor
provid
sever
benefit
facilit
track
viral
load
reduct
enabl
earli
identif
relaps
hbv
rna
level
given
time
point
predict
respons
therapi
standard
reproduc
assay
demonstr
specimen
taken
differ
time
differ
place
clinic
trial
help
evalu
test
result
viral
hepat
diseas
especi
induc
hbv
progress
seriou
patholog
outcom
eventu
hepatocellular
carcinoma
grow
bodi
evid
indic
mani
trace
element
play
import
role
number
carcinogen
process
proceed
variou
mechan
markedli
elev
cu
zn
ratio
found
patient
hepat
cirrhosi
hepatocellular
carcinoma
find
impli
level
trace
element
selenium
iron
copper
zinc
cu
zn
ratio
might
serv
biomark
increas
sever
viral
hepat
damag
hcv
affect
roughli
million
peopl
around
world
approxim
million
person
chronic
hcv
infect
us
new
infect
diagnos
year
infect
patient
die
europ
number
patient
chronic
hcv
infect
estim
million
number
hcvantibodyposit
individu
high
million
acut
hcv
infect
develop
chronic
diseas
case
set
stage
develop
liver
cirrhosi
hepatocellular
carcinoma
introduct
approv
immunoassay
eia
reduc
incid
hcv
transmiss
via
blood
transfus
first
test
administ
patient
clinic
liver
diseas
anoth
test
avail
hcv
immunoblot
assay
method
limit
use
howev
period
sever
week
separ
infect
seroconvers
addit
loss
antibodi
persist
infect
individu
report
anoth
monitor
method
measur
level
liver
enzym
alanin
aminotransferas
alt
also
give
mislead
result
fluctuat
correl
level
hcv
exampl
alt
level
may
normal
therapi
despit
persist
detect
level
hcv
rna
hepat
damag
minim
develop
yet
alt
level
may
remain
normal
activ
hcv
infect
ill
hcv
eg
alcohol
may
also
produc
abnorm
alt
valu
complic
diagnosi
direct
detect
hcv
valuabl
follow
situat
diagnosi
neonat
born
seroposit
mother
diagnosi
hcv
infect
seroneg
individu
diagnosi
organ
transplant
recipi
assess
antivir
therapi
interferonalpha
although
recommend
treatment
chronic
hcv
infect
involv
cours
combin
ribavirin
rbv
therapi
cure
hcv
respons
even
lower
africanamerican
popul
addit
limit
efficaci
treatment
often
poorli
toler
side
effect
prevent
patient
complet
therapi
reason
identif
biomark
respons
treatment
high
prioriti
genet
polymorph
near
gene
encod
report
associ
approxim
twofold
chang
respons
treatment
among
patient
european
ancestri
africanamerican
ge
et
al
almost
favor
respons
genotyp
erad
viru
less
favor
respons
genotyp
genotyp
lead
better
respons
substanti
greater
frequenc
european
african
popul
genet
polymorph
also
explain
approxim
half
differ
respons
rate
africanamerican
patient
european
ancestri
hand
among
african
american
carri
cc
genotyp
treatment
respons
higher
treatment
respons
observ
among
individu
european
descent
tt
genotyp
favor
c
allel
also
tend
found
less
frequent
chronic
hcv
infect
suggest
role
overal
viral
clearanc
unexpectedli
though
author
report
c
allel
actual
appear
link
higher
rather
lower
baselin
viral
load
research
need
determin
whether
newli
identifi
snp
biomark
import
genet
chang
whether
chang
directli
influenc
treatment
outcom
import
neg
prognost
biomark
hcv
infect
given
mediat
chemoattract
activ
lymphocyt
counterintuit
correl
therapeut
nonrespons
plasma
level
protein
predict
prior
therapi
initi
efficaci
treat
chronic
hcv
infect
peginterferon
ribavirin
prognost
test
develop
hcv
base
result
casroug
et
al
sarsassoci
coronaviru
sarscov
confirm
pathogen
sar
sever
compani
work
develop
diagnost
sar
viru
base
detect
viru
cytokin
growth
factor
marker
import
indic
inflammatori
respons
infect
cytokin
profil
also
provid
useful
tool
diagnosi
manag
sar
diseas
acut
infect
caus
rapid
increas
cytokin
level
exagger
respons
high
viral
load
detriment
individu
huge
elev
varieti
cytokin
marker
may
alert
clinician
sever
infect
ensur
prioriti
patient
manag
immedi
prevent
spread
marker
elev
sar
ifng
cytokin
respons
shown
affect
mortal
morbid
patient
communic
diseas
biochip
array
technolog
randox
laboratori
offer
blood
test
system
offer
rapid
cytokin
profil
patient
sampl
system
use
panel
approach
diagnost
profil
enabl
simultan
measur
numer
marker
minut
eas
use
minim
oper
intervent
key
benefit
system
measur
quantifi
mani
clinic
marker
risk
infect
laboratori
personnel
limit
sampl
handl
fulli
autom
onboard
dispos
compart
ensur
isol
contamin
wast
system
boast
test
throughput
cytokin
test
result
per
hour
enabl
rapid
profil
numer
patient
within
time
constraint
regul
major
caus
aid
world
retroviru
hiv
type
worldwid
estim
million
person
infect
hiv
includ
million
individu
unit
state
hiv
infect
predominantli
sexual
transmit
disord
although
mode
transmiss
eg
infect
blood
transfus
intraven
drug
abus
via
infect
needl
well
recogn
direct
detect
difficult
small
number
cell
harbor
viru
small
number
provir
copi
exist
infect
cell
viral
genom
tendenc
toward
transcript
dormanc
nevertheless
number
assay
develop
detect
presenc
infect
quantifi
level
viru
blood
infect
individu
eia
test
detect
quantif
antigen
western
blot
latex
agglutin
radioimmunoprecipit
immunofluoresc
detect
antibodi
viral
cultur
isol
semiquantif
hivassoci
neuropsycholog
impair
frequent
among
infect
patient
incid
hiv
dementia
declin
sinc
introduct
haart
therapi
zidovudin
lamivudin
ritonavir
boost
indinavir
improv
neurocognit
function
parallel
normal
csf
neural
marker
nfl
tau
gfap
level
declin
csf
serum
neopterin
csf
plasma
rna
level
apolipoprotein
b
mrnaedit
enzym
catalyt
polypeptidelik
also
known
novel
cellular
factor
innat
immun
inhibit
hiv
replic
vitro
caus
g
hypermut
consequ
reduc
rel
infect
viru
produc
infect
cell
quantif
mrna
level
patient
sampl
prognost
indic
innat
hivaid
diseas
resist
predict
whether
viral
infect
patient
categor
long
term
nonprogressor
ltnp
much
slower
diseas
progress
rate
also
provid
method
predict
level
cell
patient
well
method
optim
antivir
therapi
viral
infect
patient
signific
implic
new
develop
diagnost
tool
therapeut
target
treat
viral
infect
parasit
infect
still
endem
develop
countri
role
biomark
two
common
parasit
infect
malaria
schistosomiasi
discuss
biomark
studi
parasit
infect
complic
simultan
infect
multipl
parasit
individu
incid
sever
malaria
infect
continu
rise
mani
part
world
situat
exacerb
emerg
multidrug
resist
plasmodium
falciparum
p
vivax
two
import
human
malaria
parasit
malaria
complex
infecti
diseas
host
respons
infect
depend
upon
parasit
stage
parasit
virul
factor
host
genet
background
diagnosi
establish
identif
parasit
blood
smear
still
need
understand
molecular
process
regul
transcript
activ
gene
network
involv
pathogenesi
protect
diseas
may
provid
insight
protect
mechan
immun
aid
design
effect
vaccin
analysi
gene
express
profil
identifi
set
host
biomark
distinguish
lethal
nonleth
blood
stage
murin
malaria
infect
p
yoelii
multipl
biolog
replic
sampl
cours
infect
use
establish
statist
valid
set
differenti
express
gene
gene
correl
intens
infect
use
identifi
pathway
cellular
process
relat
metabol
perturb
erythropoiesi
bcell
immun
respons
innat
cellular
immun
respons
provid
insight
transcript
regulatori
mechan
influenc
pathogenesi
diseas
host
recoveri
infect
immun
respons
human
p
falciparum
p
vivax
malaria
may
share
mani
similar
featur
global
gene
express
program
observ
murin
malaria
import
differ
express
profil
human
infect
clinic
experiment
malaria
depend
type
tissu
peripher
blood
bone
marrow
spleen
brain
stage
infect
earli
asymptomat
versu
clinic
malaria
studi
acquisit
mainten
antimalari
antibodi
depend
exposur
malaria
infect
antibodi
might
use
biomark
transmiss
intens
measur
antiboi
serolog
test
may
detect
variat
malaria
transmiss
time
invalu
monitor
trend
malaria
endem
effect
malaria
control
program
drakeley
et
al
molecular
biomark
investig
assess
resist
antimalari
drug
conclus
inform
avail
yet
effort
use
plasma
level
circul
parasit
dna
estim
sequest
load
p
falciparum
success
far
import
identifi
individu
infect
p
falciparum
risk
develop
seriou
complic
cerebr
malaria
serum
ratio
promis
clinic
inform
biomark
cerebr
malaria
lovegrov
et
al
studi
address
use
prognost
biomark
potenti
therapeut
target
sever
malaria
schistosomiasi
second
preval
human
parasit
diseas
malaria
affect
million
peopl
worldwid
egg
produc
infect
schistosoma
mansoni
produc
complex
uniqu
proteinand
lipidlink
glycan
import
activ
modul
host
immun
respons
current
diagnosi
schistosomiasi
ideal
egg
detect
microscopi
specif
lack
sensit
suffer
highli
fluctuat
egg
output
antibodybas
diagnosi
sensit
fail
reliabl
identifi
activ
infect
antigendetect
base
assay
number
advantag
fail
detect
minim
infect
prompt
search
biomark
diseas
scientist
discov
addit
glycoprotein
glycolipid
antigen
schistosoma
egg
also
excret
uniqu
unconjug
oligosaccharid
identifi
use
affin
purif
method
base
specif
antiglycan
mab
oligosaccharid
appear
biomark
infect
urin
infect
individu
detect
mass
spectrometri
identif
new
small
molecul
biomark
may
lead
new
eggload
relat
assay
light
infect
schistosomiasi
may
also
use
measur
infect
morbid
